| Recruiting | Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cance NCT07416240 | Hainan Cancer Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment o NCT07138846 | Shanghai Miracogen Inc. | Phase 3 |
| Not Yet Recruiting | A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastati NCT07026123 | RenJi Hospital | — |
| Recruiting | Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer NCT07006077 | Hangzhou Converd Co., Ltd. | Phase 2 |
| Recruiting | Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemothera NCT06821503 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer NCT06492941 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 |
| Not Yet Recruiting | SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer NCT06422156 | Peking University Third Hospital | Phase 2 |
| Not Yet Recruiting | A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced NCT06329947 | Rui-hua Xu, MD, PhD | Phase 2 |
| Completed | Statin Addition to Chemotherapy for Advanced Pancreatic Cancer NCT06241352 | Changhai Hospital | Phase 2 |
| Recruiting | A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer NCT06111274 | Abbisko Therapeutics Co, Ltd | Phase 2 |
| Recruiting | Olaparib in PALB2 Advanced Pancreatic Cancer NCT06078787 | Azienda Ospedaliero-Universitaria di Modena | Phase 2 |
| Recruiting | Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer NCT05916261 | Ruijin Hospital | EARLY_Phase 1 |
| Unknown | Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer NCT05580445 | Shouyao Holdings (Beijing) Co. LTD | Phase 1 / Phase 2 |
| Recruiting | Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients NCT05380414 | Centre Leon Berard | N/A |
| Unknown | Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer NCT05298020 | The Affiliated Hospital of Xuzhou Medical University | Phase 2 |
| Terminated | A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer NCT05657418 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 |
| Unknown | Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer NCT05162118 | Zhejiang University | Phase 1 / Phase 2 |
| Unknown | A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer NCT05100329 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Active Not Recruiting | ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies NCT05085548 | ProDa BioTech, LLC | Phase 1 |
| Unknown | IMC001 for Clinical Research on Advanced Digestive System Malignancies NCT05028933 | Zhejiang University | Phase 1 |
| Unknown | A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer NCT04928625 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer NCT04931381 | Changhai Hospital | Phase 3 |
| Unknown | Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer NCT04803851 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Completed | A Study of Irinotecan Liposome in Advanced Pancreatic Cancer NCT04796948 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Unknown | The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Can NCT05438797 | Sizhen Wang | EARLY_Phase 1 |
| Terminated | APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma NCT04643405 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Unknown | Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy NCT04707118 | Fudan University | Phase 1 |
| Completed | Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-P NCT04617067 | Cancer Trials Ireland | Phase 2 |
| Completed | Pancreatic Adenocarcinoma Signature Stratification for Treatment NCT04469556 | University Health Network, Toronto | Phase 2 |
| Unknown | Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. NCT04482257 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of A NCT04239001 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | N/A |
| Completed | A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer NCT04228601 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patie NCT04217096 | Fudan University | Phase 4 |
| Active Not Recruiting | 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma NCT04098081 | University of Maryland, Baltimore | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies NCT04104672 | Arcus Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer NCT04137536 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors NCT03889795 | Danae Hamouda, MD | Phase 1 |
| Completed | Web-based Treatment Information Tool for People With Advanced Pancreatic Cancer NCT03632850 | Bournemouth University | — |
| Unknown | Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer NCT03662035 | Changzhou No.2 People's Hospital | Phase 2 |
| Withdrawn | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer NCT03509298 | Fuda Cancer Hospital, Guangzhou | Phase 2 |
| Completed | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic NCT03331562 | Translational Genomics Research Institute | Phase 2 |
| Completed | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreat NCT03336216 | Bristol-Myers Squibb | Phase 2 |
| Completed | QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Pacli NCT02559674 | Altor BioScience | Phase 1 |
| Completed | Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer NCT03415802 | Aiping Zhou | Phase 2 |
| Completed | Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer NCT02101580 | Polaris Group | Phase 1 |
| Unknown | Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer NCT02135822 | Chinese PLA General Hospital | Phase 2 |
| Unknown | Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer NCT02124317 | Chinese PLA General Hospital | Phase 2 |
| Completed | Supportive Care Intervention-Pancreas NCT01885884 | University of Pittsburgh | N/A |
| Completed | Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adeno NCT01764477 | Prism Pharma Co., Ltd. | Phase 1 |
| Completed | Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer NCT02382263 | PH Research, S.L. | Phase 1 / Phase 2 |
| Completed | A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer NCT01303172 | Immodulon Therapeutics Ltd | Phase 2 |
| Completed | Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer NCT01010945 | OSI Pharmaceuticals | Phase 1 |
| Completed | Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer NCT01048320 | Royal Marsden NHS Foundation Trust | Phase 1 |